miR‐99a‐5p modulates doxorubicin resistance via the COX‐2/ABCG2 axis in triple‐negative breast cancer: from the discovery to in vivo studies

• Iris Garrido‐Cano,
• Anna Adam‐Artigues,
• Ana Lameirinhas,
• Juan F. Blandez,
• Vicente Candela‐Noguera,
• Federico Rojo,
• Sandra Zazo,
• Juan Madoz‐Gúrpide,
• Ana Lluch,
• Begoña Bermejo,
• Felix Sancenón,
• Juan Miguel Cejalvo,
• Ramón Martínez‐Máñez,
• Pilar Eroles

Affiliations

Iris Garrido‐Cano

Biomedical Research Institute INCLIVA Valencia 46010 Spain

Anna Adam‐Artigues

Biomedical Research Institute INCLIVA Valencia 46010 Spain

Ana Lameirinhas

Biomedical Research Institute INCLIVA Valencia 46010 Spain

Juan F. Blandez

Bioengineering, Biomaterials and Nanomedicine Networking Biomedical Research Centre (CIBER‐BBN) Madrid 28029 Spain

Vicente Candela‐Noguera

Interuniversity Research Institute for Molecular Recognition and Technological Development (IDM) Polytechnic University of Valencia University of Valencia Valencia 46010 Spain

Federico Rojo

Biomedical Research Networking Center in Oncology (CIBERONC) Madrid 28029 Spain

Sandra Zazo

Department of Pathology Fundación Jiménez Díaz University Hospital Health Research Institute Madrid 28040 Spain

Juan Madoz‐Gúrpide

Department of Pathology Fundación Jiménez Díaz University Hospital Health Research Institute Madrid 28040 Spain

Ana Lluch

Biomedical Research Institute INCLIVA Valencia 46010 Spain

Begoña Bermejo

Biomedical Research Institute INCLIVA Valencia 46010 Spain

Felix Sancenón

Bioengineering, Biomaterials and Nanomedicine Networking Biomedical Research Centre (CIBER‐BBN) Madrid 28029 Spain

Juan Miguel Cejalvo

Biomedical Research Institute INCLIVA Valencia 46010 Spain

Ramón Martínez‐Máñez

Bioengineering, Biomaterials and Nanomedicine Networking Biomedical Research Centre (CIBER‐BBN) Madrid 28029 Spain

Pilar Eroles

Biomedical Research Institute INCLIVA Valencia 46010 Spain